Duration of adjuvant trastuzumab: shorter beats longer
Mené sur 3 105 patientes atteintes d'un cancer du sein HER2+, cet essai multicentrique international (HERA) compare, du point de la survie sans progression, l'efficacité du trastuzumab en traitement adjuvant pendant un an ou deux ans
Trastuzumab is a monoclonal antibody that binds to the HER2 tyrosine kinase. When given with chemotherapy, trastuzumab extends survival of breast cancer patients with HER2-positive cancer compared with chemotherapy alone. The recommended duration of trastuzumab treatment is 12 months in the adjuvant setting, 4 but little evidence exists to support this time period. 12 months of treatment became the accepted standard because it was the only duration assessed in the large trials that established s ...
The Lancet , commentaire, 2012